{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=8&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Tucson",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 5387,
    "total_pages": 539,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=9&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=7&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T22:33:43.450Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01483898",
      "title": "An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "Ixmyelocel-T",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vericel Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "35 Years to 90 Years"
      },
      "enrollment_count": 41,
      "start_date": "2012-02",
      "completion_date": "2014-03-25",
      "has_results": false,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 86,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01483898"
    },
    {
      "nct_id": "NCT04994899",
      "title": "Aiberry AI Mental Health Screening Platform",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Depression",
        "Anxiety",
        "Healthy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Aiberry, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "13 Years to 79 Years"
      },
      "enrollment_count": 800,
      "start_date": "2022-09-22",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 3,
      "location_summary": "Tucson, Arizona • Washington D.C., District of Columbia • New York, New York",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04994899"
    },
    {
      "nct_id": "NCT00401687",
      "title": "DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ventricular Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lantheus Medical Imaging",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2006-07",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2011-05-20",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Washington DC",
          "state": "Maryland"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401687"
    },
    {
      "nct_id": "NCT05483907",
      "title": "To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "BBT-877",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bridge Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2023-04-12",
      "completion_date": "2025-02-23",
      "has_results": false,
      "last_update_posted_date": "2025-04-01",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05483907"
    },
    {
      "nct_id": "NCT01369511",
      "title": "A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscular Atrophy"
      ],
      "interventions": [
        {
          "name": "LY2495655",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2011-07",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Laguna Hills, California • Lakewood, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369511"
    },
    {
      "nct_id": "NCT00827008",
      "title": "Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subjective Tinnitus"
      ],
      "interventions": [
        {
          "name": "Neramexane mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Pharmaceuticals GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 821,
      "start_date": "2009-01",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-11-28",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 31,
      "location_summary": "Tucson, Arizona • Burbank, California • Fresno, California + 27 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00827008"
    },
    {
      "nct_id": "NCT00241540",
      "title": "Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "GERD"
      ],
      "interventions": [
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 808,
      "start_date": "2001-01",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2011-01-24",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Anaheim, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241540"
    },
    {
      "nct_id": "NCT02587325",
      "title": "Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Hypertension"
      ],
      "interventions": [
        {
          "name": "nab-sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aadi Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2017-04-01",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 6,
      "location_summary": "Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02587325"
    },
    {
      "nct_id": "NCT00064974",
      "title": "Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "CC-5013",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2003-06",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2013-04-04",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 38,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Berkeley, California + 28 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064974"
    },
    {
      "nct_id": "NCT03654274",
      "title": "SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "51 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 51 Years · Female only"
      },
      "enrollment_count": 802,
      "start_date": "2018-05-22",
      "completion_date": "2023-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-10-22T22:33:43.450Z",
      "location_count": 60,
      "location_summary": "Andalusia, Alabama • Scottsdale, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03654274"
    }
  ]
}